About: Hematopoietic stem cell transplantation for severe aplastic anemia

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Hematopoietic stem cell transplantation for severe aplastic anemia—experience of an institute in Taiwan Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Hematopoietic stem cell transplantation for severe aplastic anemia—experience of an institute in Taiwan
Creator	Chen, · Liu, J Wang, · Yan, · Bai, L Chao, T Chiou, T Hsiao, · Yen, ·
Source	PMC
abstract	Hematopoietic stem cell transplantation (HSCT) is an accepted treatment strategy for patients with severe aplastic anemia (SAA). We report our experience in a general hospital in Taiwan. From March 1985 to July 2001, 79 consecutive SAA patients, 46 male and 33 female, with a median age of 22 (4–43) years, received 80 courses of transplantation. Cyclophosphamide and total body radiation were used for the conditioning regimen, and cyclosporine-A and methotrexate for graft-versus-host disease (GVHD) prevention. Patients were followed for a median of 39 months (from 8 days to 194 months). Myeloid and platelet engraftment occurred in a median of 15 (8–27) days and 18 (8–77) days, respectively. Three patients had primary and three patients secondary graft failure. Five patients (6.8%) had grade II–IV acute GVHD in 73 evaluable patients. Chronic GVHD occurred in 23 (34.8%) patients, with extensive stage in six. Only two patients had CMV disease. The projected 3- and 5-year overall survival rates estimated by the Kaplan-Meier method were 76.08 and 74.13%, respectively. Age at transplant, non-sibling donor, mononuclear cell dose, grade II–IV acute GVHD, interval from diagnosis to transplant, and red blood cell and platelet transfusion before transplant were poor prognostic factors for overall survival by univariate analysis. Grade II–IV acute GVHD was the only prognostic factor affecting overall survival after multivariate Cox regression analysis (P=0.040). In conclusion, SAA patients receiving HSCT have good long-term survival. The low incidence of acute GVHD in our patients may be related to ethnicity.
has issue date	2003-10-03(xsd:dateTime)
bibo:doi	10.1007/s00277-003-0781-3
bibo:pmid	14530878
has license	no-cc
sha1sum (hex)	c342e5cdba10e5c95d6f9e8a19551c0eb79310f0
schema:url	https://doi.org/10.1007/s00277-003-0781-3
resource representing a document's title	Hematopoietic stem cell transplantation for severe aplastic anemia—experience of an institute in Taiwan
has PubMed Central identifier	PMC7102357
has PubMed identifier	14530878
schema:publication	Ann Hematol
resource representing a document's body	covid:c342e5cdba10e5c95d6f9e8a19551c0eb79310f0#body_text
is schema:about of	named entity 'transplantation' named entity 'patients' named entity 'GVHD' named entity 'total' named entity 'general hospital' named entity 'graft-versus-host disease' named entity 'GVHD' named entity 'conditioning regimen' named entity 'projected' named entity 'acute' named entity 'MARCH' named entity 'USED' named entity 'POOR' named entity 'CONSECUTIVE' named entity 'LONG-TERM SURVIVAL' named entity 'HAVE' named entity 'OCCURRED' named entity 'AGE' named entity 'PLATELET TRANSFUSION' named entity 'REPORT' named entity 'GVHD' named entity 'GVHD' named entity 'regression analysis' named entity 'days' named entity 'good' named entity 'Hematopoietic stem cell transplantation (HSCT)' named entity 'patients' named entity 'median age' named entity 'grade' named entity 'prevention' named entity 'aplastic anemia' named entity 'platelet transfusion' named entity 'mononuclear cell' named entity 'Kaplan-Meier method' named entity 'platelet' named entity 'univariate analysis' named entity '8 days' named entity 'HSCT' named entity 'Cyclophosphamide' named entity 'GVHD' named entity 'Hematopoietic stem cell transplantation' named entity 'donor' named entity 'patients' named entity 'GVHD' named entity 'fulminant hepatitis' named entity 'bone marrow' named entity 'infertility' named entity 'Deeg' named entity 'MTX' named entity 'supportive care' named entity 'log-rank test' named entity 'cyclophosphamide' named entity 'Kaplan-Meier method' named entity 'immunosuppression' named entity 'platelet' named entity 'human T-lymphotropic virus' named entity 'total body irradiation' named entity '21%' named entity 'methotrexate' named entity 'GVHD' named entity 'IgM' named entity 'CMV' named entity 'HLA' named entity 'red blood cell' named entity 'Fresenius' named entity 'older age' named entity 'CMV' named entity 'amenorrhea' named entity '5-year survival' named entity 'stem cell transplantation' named entity 'prednisolone' named entity 'acute respiratory distress syndrome' named entity 'GVHD'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software